Institutional shares held 187 Million
6.03M calls
10.1M puts
Total value of holdings $294M
$9.46M calls
$15.8M puts
Market Cap $1.23B
771,960,000 Shares Out.
Institutional ownership 24.22%
# of Institutions 256


Latest Institutional Activity in OPK

Top Purchases

Q3 2024
Rubric Capital Management LP Shares Held: 48.7M ($77.4M)
Q3 2024
Citadel Advisors LLC Shares Held: 2.5M ($3.98M)
Q3 2024
Millennium Management LLC Shares Held: 2.48M ($3.94M)
Q3 2024
Vanguard Group Inc Shares Held: 29.2M ($46.5M)
Q3 2024
Assenagon Asset Management S.A. Shares Held: 1.49M ($2.37M)

Top Sells

Q3 2024
Group One Trading, L.P. Shares Held: 221K ($351K)
Q3 2024
Charles Schwab Investment Management Inc Shares Held: 4.21M ($6.7M)
Q3 2024
State Street Corp Shares Held: 8.72M ($13.9M)
Q3 2024
Northern Trust Corp Shares Held: 3.53M ($5.62M)
Q3 2024
Invesco Ltd. Shares Held: 6.03M ($9.59M)

About OPK

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.


Insider Transactions at OPK

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
14.4M Shares
From 14 Insiders
Grant, award, or other acquisition 2.81M shares
Open market or private purchase 11.6M shares
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on OPK

Follow OPKO HEALTH, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells OPK shares.

Notify only if

Insider Trading

Get notified when an Opko Health, Inc. insider buys or sells OPK shares.

Notify only if

News

Receive news related to OPKO HEALTH, INC.

Track Activities on OPK